$3.38-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toSep 30, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $97.3K | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Corbus Pharmaceuticals Holdings, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“During the third quarter, we achieved key milestones with both clinical programs: initiating dosing in our TEMPO-1 Phase 3 study of sutantatug envedotin in oropharyngeal cancer and announcing positive topline data from our CANYON-1 Phase 1b study of CRB-913 in obesity,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes sutantatug envedotin, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Corbus Pharmaceuticals Holdings, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.